english.prescrire.org > Spotlight > "Spotlight" > Tirzepatide (Mounjaro°) in type 2 diabetes

"Spotlight"

Tirzepatide (Mounjaro°) in type 2 diabetes

 Marketing Authorisations   A tirzepatide solution for subcutaneous injection has been authorised in the European Union for use in adults with type 2 diabetes, either as monotherapy when metformin use is considered inappropriate, or in combination with other glucose lowering-drugs. In these situations, is tirzepatide more effective than a GLP-1 agonist in preventing the complications of diabetes? And what are its adverse effects?
Full article available for download by subscribers (4 pages)

©Prescrire 1 November 2024

Source: "Tirzepatide (Mounjaro°) in type 2 diabetes" Prescrire Int 2024; 33 (264): 257-259. Subscribers only.

Enjoy full access to Prescrire International, and support independent information